Medicare To Cover At-Home Test To Detect Organ Rejection After Kidney Transplant Surgery
Executive Summary
US Medicare has issued a local coverage determination (LCD) for NephroSant’s QSant test, which uses artificial intelligence to score a patient’s likelihood of experiencing organ rejection after transplant. Early detection of rejection could be a game-changer for organ recipients.
You may also be interested in...
Organ Transplant Surgery Has Advanced – Organ Storage Should Too
The CEO of Organ Recovery Systems tells Medtech Insight that the latest technology in organ preservation and transport could mean greater access to viable organs and more saved lives.
Proposed ESRD Reimbursement Changes Look To Improve Equity In Care For Patients With Chronic Kidney Disease
Changes to the mandatory payment model now used by the US Centers for Medicare & Medicaid Services (CMS) for kidney disease would encourage facilities to provide treatment to lower income patients.
News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared
This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.